Arecor Therapeutics (LSE:AREC) EBITDA Margin % : -134.30% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Arecor Therapeutics EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Arecor Therapeutics's EBITDA for the six months ended in Dec. 2023 was £-3.90 Mil. Arecor Therapeutics's Revenue for the six months ended in Dec. 2023 was £2.90 Mil. Therefore, Arecor Therapeutics's EBITDA margin for the quarter that ended in Dec. 2023 was -134.30%.

Arecor Therapeutics EBITDA Margin % Historical Data

The historical data trend for Arecor Therapeutics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arecor Therapeutics EBITDA Margin % Chart

Arecor Therapeutics Annual Data

Trend

May17

May18

May19

Dec20

Dec21

Dec22

Dec23

EBITDA Margin %

Get a 7-Day Free Trial

-358.16

-192.11

-583.07

-418.73

-183.47

Arecor Therapeutics Semi-Annual Data
	May18	May19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EBITDA Margin %	Get a 7-Day Free Trial					-496.42	-741.13	-288.07	-269.02	-134.30

Competitive Comparison of Arecor Therapeutics's EBITDA Margin %

For the Biotechnology subindustry, Arecor Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Arecor Therapeutics's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arecor Therapeutics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Arecor Therapeutics's EBITDA Margin % falls into.

Arecor Therapeutics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Arecor Therapeutics's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-8.39	/	4.573
	=	-183.47 %

Arecor Therapeutics's EBITDA Margin % for the quarter that ended in Dec. 2023 is calculated as

EBITDA Margin %	=	EBITDA (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-3.9	/	2.904
	=	-134.30 %

Arecor Therapeutics (LSE:AREC) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Arecor Therapeutics EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Arecor Therapeutics's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Arecor Therapeutics (LSE:AREC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arecor Therapeutics PLC (LSE:AREC) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

6UI:Germany

Address

Chesterford Research Park, Little Chesterford, Saffron Walden, GBR, CB10 1XL

Website

https://www.arecor.com

Arecor Therapeutics PLC is a focused biopharmaceutical company. The company is transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying an innovative proprietary formulation technology platform, Aresta. It is developing a portfolio of proprietary products in diabetes and other indications and working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of their therapies. Geographically, it operates in the UK, Switzerland, the Rest of Europe, the USA, India, and the Rest of the World, out of which the majority is from the UK.